Vertex Pharmaceuticals
Vertex Pharmaceuticals works on 13 rare diseases tracked on Trial Friend, including Acromegaly, Alpha-1 Antitrypsin Deficiency, Congenital Adrenal Hyperplasia and 10 more, with 17 active clinical trials (8 recruiting) and 6 FDA-approved rare disease drugs.
Vertex Pharmaceuticals is the company that took cystic fibrosis from a disease that often killed patients before they reached adulthood and turned it into a chronic illness most patients will live decades longer with. Founded in 1989 and headquartered in Boston, Vertex trades on the NASDAQ under the ticker VRTX. The company spent more than 20 years on the underlying CFTR-modulator chemistry before its first approved cystic fibrosis drug, and the resulting franchise is the foundation of everything else it does today.
The current cornerstone CF drug is Trikafta, a triple combination of CFTR modulators that addresses the most common CFTR mutation, which is present in roughly 90% of CF patients. Trikafta has dramatically improved lung function, weight gain, and survival outlook for the patients eligible for it. In December 2024, the FDA approved Alyftrek, the next-generation CF therapy combining vanzacaftor, tezacaftor, and deutivacaftor in a once-daily pill that further extends the patient population covered. Cystic fibrosis is caused by inherited mutations in the CFTR chloride channel, which lead to thick mucus buildup in the lungs and digestive tract. The Vertex modulator program has been one of the more transformative arcs in modern medicine.
Beyond CF, Vertex co-developed Casgevy (exagamglogene autotemcel) with CRISPR Therapeutics, which became the first CRISPR-based gene-editing therapy approved by the FDA. Casgevy treats sickle cell disease and transfusion-dependent beta thalassemia by editing patient cells outside the body to reactivate fetal hemoglobin, which restores healthy red blood cell function. On July 1, 2026 the FDA extended Casgevy to people aged 2 and older. It had been approved from age 12. Casgevy represented a watershed moment for the field of gene editing as a clinical reality.
In 2025, Vertex broadened beyond rare genetics with the FDA approval of Journavx (suzetrigine) in January, the first novel non-opioid acute pain medicine in over two decades. In 2024 Vertex also acquired Alpine Immune Sciences for $4.9 billion, gaining povetacicept, a dual BAFF/APRIL antagonist that met its primary endpoint at a planned Week 36 interim analysis of the Phase 3 RAINIER trial for IgA nephropathy, with a 49.8% placebo-adjusted reduction in urine protein-to-creatinine ratio. Vertex completed its rolling BLA submission for povetacicept in March 2026, and the FDA accepted it for accelerated approval review with a decision date of November 30, 2026. The pipeline also includes inaxaplin (VX-147) for APOL1-mediated kidney disease, which mostly affects people of African ancestry, in the Phase 2/3 AMPLITUDE trial, and zimislecel, a stem-cell-derived islet therapy for type 1 diabetes in a Phase 1/2/3 study. Vertex said in August 2026 it would give updated zimislecel timelines later in the year. On September 1, 2026, Vertex completed its approximately $10 billion acquisition of Crinetics Pharmaceuticals, adding the marketed oral acromegaly drug Palsonify (paltusotine) and moving Vertex into rare endocrine disease. The deal also brought in atumelnant, in Phase 3 for congenital adrenal hyperplasia.
Vertex Pharmaceuticals Drug Pipeline
Vertex Pharmaceuticals has 17 active clinical trials across 4 development stages, with 8 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline counts the active and recruiting trials listed on this page, from ClinicalTrials.gov. For companies that work outside rare disease, we list only trials for rare diseases we track, so the company's full pipeline may be larger.
Vertex Pharmaceuticals Clinical Trials (17)
Active and recruiting clinical trials sponsored by Vertex Pharmaceuticals, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
One email when the decision is public, with what it means in plain language, plus new trials and FDA news for the condition you follow. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for IgA Nephropathy. Turn any of these off from the link in every email.
Vertex Pharmaceuticals FDA-Approved Drugs (6)
Medications developed or marketed by Vertex Pharmaceuticals that have received U.S. Food and Drug Administration approval. Drug data is sourced from the openFDA database and includes brand names, generic names, approval dates, and matched rare disease indications. Where a drug treats a condition covered by Trial Friend, the disease name links directly to that disease page.
| Drug Name | Brand Name | Rare Diseases | Approval Date |
|---|---|---|---|
| VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] | ALYFTREK oral | Dec 20, 2024 | |
| IVACAFTOR Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] | Kalydeco oral | Jan 31, 2012 | |
| LUMACAFTOR AND IVACAFTOR Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] | ORKAMBI oral | Jul 2, 2015 | |
| TEZACAFTOR AND IVACAFTOR | SYMDEKO | Feb 12, 2018 | |
| ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR | Trikafta | Oct 21, 2019 |
Vertex Pharmaceuticals Trial Locations
Vertex Pharmaceuticals clinical trials are running at 613 sites in 30 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (13)
Diseases targeted by Vertex Pharmaceuticals's clinical trial and drug development programs
Acromegaly is a rare hormonal disorder caused by excessive growth hormone production, typically from a pituitary adenoma, resulting in abnormal growth of hands, feet, and facial features. It also caus...
Alpha-1 antitrypsin deficiency is a genetic disorder affecting the lungs and liver, caused by insufficient production of the protective protein alpha-1 antitrypsin. Without adequate protection, neutro...
Congenital adrenal hyperplasia comprises rare autosomal recessive disorders of cortisol synthesis. Over 90% result from 21-hydroxylase deficiency. Salt-wasting and virilizing forms present with differ...
Cystic fibrosis is an autosomal recessive genetic disorder affecting the CFTR protein, which normally regulates chloride transport. Defective CFTR causes thick, sticky secretions in the lungs and dige...
Focal Segmental Glomerulosclerosis (FSGS) is a kidney disease characterized by scarring of some glomeruli, the tiny filtering units that remove waste from the blood. The disease can develop on its own...
IgA nephropathy is the most common primary glomerulonephritis worldwide, caused by abnormal IgA1 antibodies depositing in the kidney's mesangium, activating complement pathways and triggering inflamma...
Patient Resources
Organizations and resources related to Vertex Pharmaceuticals's rare disease focus areas
Frequently Asked Questions About Vertex Pharmaceuticals
Common questions about Vertex Pharmaceuticals's rare disease programs, clinical trials, and treatments.